CML

Question 1

Bosutinib dose and AEs

Answer 1

400mg daily

Diarrhea, pleural effusion

Question 2

Dasatinib dose and AEs

Answer 2

100mg daily

Pleural effusions, pulmonary HTN, bleeding

Question 3

Nilotinib dose and AEs

Answer 3

300mg BID

Prolonged QT, sudden death, pancreatitis, increased glucose, peripheral arterial occlusive disease

Question 4

Imatinib dose and AEs

Answer 4

400mg day, can increase to 600-800

Fatigue, MSK pain, diarrhea, edema, cytopenias

Question 5

3 month TKI failure criteria

Answer 5

Non-complete hematologic response and/or Ph+ >95%

If BCR-ABL1 >10%, switch TKI or increase imatinib dose

Question 6

6 month TKI failure criteria

Answer 6

BCR-ABL1 > 10% and/or Ph+ >35%

Question 7

12 month TKI failure criteria

Answer 7

BCR-ABL1 > 1% and/or Ph+ > 0

Question 8

Accelerated phase criteria

Answer 8

10-19% blasts in blood or marrow; >= 20% blood basophils

Question 9

Accelerated phase treatment

Answer 9

Start with higher dose of 2nd gen TKI

Dasatinib 140mg, nilotinib 400mg BID, or bosutinib 500mg

Question 10

Ponatinib dose and AEs

Answer 10

45mg daily

Ischemic arterial events